Using meta-analysis methodology, we compared the clinical outcomes for 769 patients with hepatic cystic echinococcosis treated with percutaneous aspiration-injection-reaspiration (PAIR) plus albendazole or mebendazole (group 1) with 952 era-matched historical control subjects undergoing surgical intervention (group 2). The rate of clinical and parasitologic cure ( ) was greater in patients receiving PAIR plus che-P ! .0001 motherapy. Disease recurrence ( ), major complications (anaphylaxis, biliary fistula, cyst infection, P ! .0001 liver/intra-abdominal abscess, and sepsis; ), minor complications ( ), and death ( ) P ! .0001 P ! .0001 P ! .0824 occurred more frequently among surgical control subjects. Fever ( ) and minor allergic reactions subjects P ! .002 ( ) were more common among PAIR-treated subjects. The mean durations of hospital stay were 2.4 P ! .0001 days for group 1 and 15.0 days for group 2 ( ). Compared with surgery, PAIR plus chemotherapy is P ! .001 associated with greater clinical and parasitologic efficacy; lower rates of morbidity, mortality, and disease recurrence; and shorter hospital stays.
for the cystic lesions seen in hydatid disease, followed by the lung, the brain, and other viscera [1] .
The optimal treatment for hepatic cystic echinococcosis has not been fully determined. Historically, management of hydatid cysts in the liver typically involved an open surgical approach with meticulous operative site packing and a variety of conservative and radical operative techniques [2] [3] [4] . Percutaneous aspiration of a documented or suspected hydatid cyst was long considered to be contraindicated to avoid the risk of leakage of cyst contents, which can lead to anaphylaxis and seeding of intraperitoneal structures. Since the advent of drug therapy effective against Echinococcus species, many health care centers now advocate an approach consisting of pre-and postoperative chemotherapy with albendazole or mebendazole, combined with percutaneous drainage (consisting of puncture, aspiration, injection, and reaspiration [PAIR] ) of hepatic hydatid cysts [4] [5] [6] [7] [8] . However, the technique has not been universally accepted. We sought to compare the safety and effectiveness of percutaneous drainage plus albendazole or mebendazole with conservative and radical surgical interventions in patients with hepatic cystic echinococcosis. We conducted a meta-analysis of 21 relevant articles in the Englishlanguage literature that involved 769 patients with 1072 hepatic cysts undergoing PAIR and that provided adequate details of treatment, complications, outcome, and follow-up.
PATIENTS AND METHODS
A comprehensive analysis of the literature published from 1985 through April 2002 was conducted using a computerized search of the MEDLINE database, perusal of Index Medicus and Current Contents, and review of bibliographies of articles and major infectious diseases and tropical medicine textbooks to identify clinical studies in which PAIR drainage plus albendazole or mebendazole was used in the treatment of patients with hepatic cystic echinococcosis. Keywords were "hepatic cystic echinococcosis," "hepatic hydatid cysts," and "albendazole" or "mebendazole." Forty-five entries were cited; of these, 21 comparative or noncomparative studies that were published during 1990-2001 and that involved 769 albendazole-treated (15 studies; 663 subjects) or mebendazole-treated (8 studies; 106 subjects) subjects were identified that reported sufficient details of drug and percutaneous drainage regimens and clinical, parasitologic, and radiographic outcomes and were included in this review (2 studies treated patients with either albendazole or mebendazole). Cases of hepatic cystic echinococcosis were diagnosed and included in the analysis on the basis of clinical, radiographic (ultrasonographic and/or CT studies revealing either univesicular or multivesicular cysts in the liver), cytologic or parasitologic (procedural or operative specimens showing viable or nonviable scolices, hooklets, and/or fragments of laminated membrane), and/or serologic (detectable serum IgG and/ or IgM antibody titers to E. granulosus ) grounds. Patients who were pregnant or who had infected cysts at the time of initial aspiration were excluded. Data extracted from studies included initial and serial postprocedure/postoperative hepatic cyst size; dose, route, and duration of drug therapy; findings of serial clinical and biochemical examinations; results of serial serologic tests of echinococcal antibody titers; length of hospital stay; complications, including disease recurrence; and outcome.
All patients undergoing percutaneous drainage were treated with either oral albendazole (usually 10-15 mg/kg q.d.) or mebendazole (50 mg/kg q.d.), generally before and after drainage. Percutaneous drainage was performed under continuous ultrasonographic or CT guidance with close monitoring for complications, such as anaphylaxis, bronchospasm, and laryngeal edema. The procedure was typically performed in 3 steps: puncture and needle aspiration of the cyst, instillation and indwelling of a scolicidal solution for ∼20-30 min, and cyst reaspiration and final irrigation (complete cyst aspiration was generally performed a single time, but, in certain subjects, aspiration was repeated until the aspirate was clear). In 72 (9%) of 769 patients, Gharbi classification [9] type 3 and 4 cysts were managed with needle decompression and catheter drainage, with catheters left in place 1-10 days after drainage. Cyst fluid or operative tissue specimens were immediately subjected to cytologic, histopathologic, and parasitologic examinations after aspiration or catheter drainage to confirm the diagnosis and to assess the success of the drainage procedure. Viability of protoscolices was assessed by observing their motility and their staining pattern by light microscopy and staining with neutral red (demonstrating viable parasites) and methylene blue (demonstrating dead organisms) [10] .
In the studies reviewed, the following criteria were variably used to define cure or success in recipients of PAIR treatment and were accepted in formulating our definition as well: clinical disappearance of symptoms plus у1 of the following: (1) on the real-time sonograph, separation of the endocyst (germinal layer) from the pericyst and rupture of secondary vesicles in multivesicular cysts, a gradual decrease in cyst size until disappearance with no increase in size during follow-up, a small residual cyst cavity with a high level of echogenic material, or complete obliteration with a heterogeneous echopattern (pseudotumor formation); (2) on CT, an increase in the density of the cyst cavity; (3) on serologic and parasitologic examination, negative serology titers (!1:160) and absence of live protoscolices in the aspirated cyst fluid.
We defined other forms of responses as follows: "improvement" was defined as a decrease in the size of the cyst (usually р50%) and/or successful treatment of у1 cyst in patients who had 11 cyst; "recurrence" was defined as volumetric increase of a cyst and/or appearance of a cyst in the same or other organ after successful treatment; and "failure" was defined as no change in cyst size or morphology or an incomplete response to treatment. Complications of PAIR (or surgery) were defined as "major" (i.e., anaphylaxis, biliary fistula, cyst infection, liver/ intra-abdominal abscess, or sepsis) or "minor" (generally nonlife-threatening and/or nosocomial complications).
Patients were observed for у6 months, during which time serial ultrasonographic and/or CT studies were performed to assess the echopattern and residual size of the hepatic cyst cavity. Serial serum IgG and/or IgM antibodies to E. granulosus were measured by ELISA, and serologic titers of 11:160 were considered positive.
In light of advances in surgical techniques over the past 50 years, and especially because such operative improvements have been shown to significantly decrease morbidity and mortality in the surgical management of cystic hepatic echinococcosis, for comparison with PAIR, we selected era-matched (1990-2001) historical control subjects who had undergone surgical intervention for cystic hydatid disease. We identified 952 subjects from 14 previously published articles that reported suf- NOTE. The total number of patients was 769; the total number of cysts was у1088. NS, not stated.
ficient details and results of surgical management of hepatic echinococcosis. Surgical interventions consisted of both conservative and radical approaches. Conservative techniques involved simple tube drainage, marsupialization (i.e., surgical exteriorization of a cyst by resection of the anterior wall and suture of the cut edges of the remain cyst to the adjacent edges of the skin, thereby establishing a pouch of what was formally an enclosed cyst), capitonnage (i.e., surgical closure of a cyst cavity by applying sutures so as to cause approximation of the opposition surfaces), deroofing, partial simple cystectomy, or open or closed total cystectomy, with or without omentoplasty. Radical procedures included total pericystectomy, partial hepatectomy, and lobectomy. The specific tests used in the statistical interpretation of data were not always stated in the methods sections of the studies included in this analysis. For pooling and analysis, data were entered into Epi-Info, version 6.04 (Centers for Disease Control and Prevention), and analyzed by SPSS standard, version 8.0 Table 2 . Clinical, laboratory, and radiographic outcomes in 769 patients with hepatic echinococcosis treated with percutaneous drainage and albendazole or mebendazole. 
RESULTS
Clinical and treatment details for the 21 PAIR studies reviewed are shown in tables 1 and 2. Scolicidal solutions used in PAIRtreated subjects included hypertonic saline (8 studies); absolute alcohol (4 studies); hypertonic saline, with or without absolute alcohol (2 studies); hypertonic saline or absolute alcohol (2 studies); silver nitrate (1 study); hypertonic saline or silver nitrate (1 study); and mebendazole (1 study); solutions were not reported in 2 studies. When duration of treatment was precisely stated, subjects received predrainage albendazole or mebendazole for a median of 7 days (range, 4 h to 15 days) and postprocedure drug therapy for a median of 28 days (range, 4 h to 6 months). The mean duration of patient follow-up was 20.5 months, and the mean duration of hospital stay was 2.4 days. Titers of IgM and/or IgG antibody to E. granulosus generally decreased or reverted to negative with successful drainage. Tables 3 and 4 show treatment results in control subjects from the literature undergoing surgical intervention for cystic hydatid disease of the liver. Scolicides used in the surgical control subjects included hypertonic saline alone (6 studies); hypertonic saline or povidone iodine (1 study); hypertonic saline, hydrogen peroxide, or iodine (1 study); hypertonic saline or formalin (1 study); silver nitrate (1 study); and albendazole (1 study); the scolicides used were not reported in 3 studies. Four hundred nineteen control patients received albendazole or mebendazole in addition to undergoing surgery; 533 subjects underwent a surgical procedure alone. The mean duration of follow-up for surgical control subjects was 32 months, and the mean duration of hospital stay was 15.0 days ( , com-P ! .001 pared with PAIR-treated subjects).
Major reactions (i.e., anaphylaxis, cyst infection, liver or intra-abdominal abscess, sepsis, and biliary fistula) occurred in 7.9% and 25.1% of PAIR-treated and surgical control subjects, respectively ( ); minor reactions occurred and 13.1% P ! .0001 and 33% of PAIR-treated and surgical control subjects, respectively (  ; table 5 ). There was no instance of dis-P ! .0001 semination (peritoneal seeding) by PAIR. Fever (5.5% and 2.5%;
) and allergic reaction (4.8% and 0.1%; P ! .002 P ! ) were encountered more frequently in PAIR-treated sub-.0001 jects than in control subjects, respectively, but these reactions were generally managed effectively with antipyretics, intravenous fluids, and antihistamines. Comparative outcomes for PAIR-treated patients and surgical control subjects are shown in table 6. Clinical and parasitologic cure occurred in 95.8% of patients undergoing PAIR and in 89.8% of surgical controls ( ); incomplete response occurred in 2.0% and 3.2%, P ! .0001 respectively ( ); and disease recurrence occurred in P ! .1249 1.6% and 6.3%, respectively ( ). There was 1 proce-P ! .0001 dure-related death due to anaphylaxis (0.1%) in the PAIR group, compared with 7 deaths (0.7%) among surgical controls ( ). Causes of mortality in controls included pulmo-P ! .0827 nary complications (3 patients), liver failure (1 patient), myocardial infarction (1 patient), generalized peritonitis (1 patient), and spontaneous anaphylaxis (1 patient). The choice of scolicidal agent did not appear to influence outcomes (data not shown).
DISCUSSION
For decades, surgical excision was the recommended approach for hydatid cysts of the liver. With the advent of effective antiechinococcal drug treatment, ultrasonography-guided PAIR is now commonly performed in conjunction with drug therapy consisting of albendazole or mebendazole provided before and after drainage [4, 5, . The goals of surgery in hydatid disease are to inactivate the cestode parasites, evacuate the cyst cavity, remove the germinal layer, and obliterate the residual cavity. PAIR treatment satisfies all of these goals but substitutes germinal membrane sclerosing and separation by means of scolicides for surgical removal. Other techniques of percutaneous drainage for hydatid cysts have been described elsewhere [41] [42] [43] , but we chose to confine our analysis specifically to the PAIR procedure.
Percutaneous drainage of hepatic hydatid cysts without drug therapy has been reported [6-8, 11, 44, 45] . However, con- [34] , and 36%-67% [38] ). c Included diarrhea (3 cases), neutropenia (1 case), and alopecia (1 case); all were reversible but required discontinuation of drugs. d Eighteen patients required operative revision; the remaining patients were treated conservatively.
comitant pre-and postinterventional chemotherapy with albendazole or mebendazole offers the advantage of reducing the risk of disease recurrence and intraperitoneal seeding of infection that may develop via cyst rupture and spillage occurring spontaneously or during needle puncture of cysts. In this metaanalysis, we compared the clinical outcomes and rates of complication of patients with hepatic echinococcosis treated with pre-and postoperative drug therapy and percutaneous needle drainage with those of era-matched control subjects undergoing surgical intervention. Compared with patients treated surgically, we found that percutaneous drainage of hydatid cysts, or PAIR therapy, had greater clinical efficacy (i.e., a higher incidence of cure); lower rates of major and minor complications, mortality, and disease recurrence; and a shorter duration of hospitalization. There are considerable potential economic and societal savings inherent in the availability of a safe and effective nonoperative treatment modality for hydatid cyst disease that reduces the duration of hospital stays by 84%.
Although different scolicidal solutions were used among both the percutaneous drainage and surgical groups, there were no significant differences in outcomes, and we do not believe that the type of scolicidal agent by itself significantly influenced the results of this meta-analysis. Hypertonic saline (in 15%-30% concentrations) exerts its scolicidal effect by creating a strong osmotic gradient across the outer cuticular membrane of the protoscolex, which causes its lysis. A unique advantage of hypertonic saline is its high density and attenuation on CT imaging, which allows assessment of dilution of the solution within the hydatid cyst cavity, evaluation of proper contact of the solution with all internal parts of the cyst, and detection of extra-hepatic biliary communications. For multiseptate type 3 cysts or large cysts (16 cm in size), some authors advocate the use of absolute alcohol because it is a more sclerosing agent than hypertonic saline, it may destroy daughter cysts not killed by saline, and it may result in more rapid involution of the cyst cavity [12] [13] [14] [15] [16] [17] [18] [19] [20] . Alcohol should not be used, however, if preexisting biliary communication is suspected or documented, because the agent may cause a chemical cholangitis.
The availability of chemotherapeutic agents with significant activity against E. granulosus has made it possible to undertake transhepatic percutaneous drainage of hydatid cysts. However, treatment of hepatic cystic echinococcosis with the benzimidazole carbamate agents mebendazole or albendazole alone is not as effective as a combined chemotherapy-drainage approach. Mebendazole was the first compound found to have in vivo activity in hydatid disease. The drug interferes with mechanisms of glucose absorption through the wall of the parasite, leading to glycogen depletion and subsequent degenerative changes in the mitochondria and endoplasmic reticulum of the germinal cells [46] . Albendazole is more active in vitro than mebendazole and has improved gastrointestinal absorption and bioavailability, and it has better-reported clinical results as well [47] [48] [49] [50] [51] . After oral administration, albendazole achieves high concentration in blood, bile, liver tissue, cyst fluid, and cyst wall [15, 51, 52] . Both drugs may decrease the size of hydatid cysts and may lead to sterilization of cyst contents in some cases; however, without concomitant drainage, clinical and radiographic resolution is unpredictable and occurs in less than one-half of treated patients [47] [48] [49] [50] [51] [52] [53] . Although orally administered albendazole results in high serum concentrations (peaking in ∼4 h), penetration into the cyst contents is erratic. Percutaneous injection of albendazole sulfate without reaspiration has been attempted in both experimental and human subjects and results in effective scolicidal activity with little or no toxicity to the liver or biliary system, and local instillation has been suggested as an adjunctive to systemic chemotherapy [17, 54] . In conjunction with PAIR, the usual dosage of orally administered albendazole is 10-15 mg/kg per day in 2 divided doses, or as a fixed dosage of 400 mg twice per day. If mebendazole is administered, the daily dosage is 40-50 mg/kg in 3 divided doses. Patients in this meta-analysis received antiparasitic drug therapy for ∼1 week before and 4 weeks after percutaneous drainage. Hepatic and hematologic toxicities are the most frequent serious adverse effects of albendazole and mebendazole therapy. For patients receiving chemotherapy, it is probably prudent to have liver enzyme levels and complete blood counts monitored every 2 weeks during drug treatment [55] .
With serial sonographic follow-up, the radiographic response to PAIR plus albendazole therapy evolves through a series of progressive changes in echopattern. There is immediate detachment of the germinal layer (endocyst) from the pericyst after injection and aspiration of the scolicidal agent. Subsequently, there is reduction in cyst size, diminution of fluid contents, solidification of internal cyst structure (pseudotumor formation), and, in many patients, eventual radiologic disappearance. Microscopically, there is concomitant permanent damage to the germinal membrane; viable protoscolices can be accurately distinguished from nonviable protoscolices by neutral red and eosin (or methylene blue) stains, respectively [10] . Percutaneous drainage can be performed with a single needle puncture for both univesicular and multivesicular cysts [19, 21] .
Complications of PAIR therapy with albendazole or mebendazole are generally well tolerated. Infections can be managed with systemic antimicrobial therapy; leakage during drainage may lead to fever, urticaria, transient hypotension, or anaphylaxis, but these can be anticipated and effectively managed with antipyretics, intravenous fluids, and subcutaneous epinephrine. Cyst-biliary communications (biliary rupture and fistula formation) developing after PAIR and caused by cyst decompression can usually be managed endoscopically [20] . Cholangiography or endoscopic retrograde cholangiopancreatography is recommended before any percutaneous drainage to inject contrast dye and detect connections with the biliary tree. Biliary connections may be hidden before endoscopic retrograde cholangiopancreatography because of distention of cysts before aspiration, but they become visible after injection of the contrast material.
Limitations or biases of this meta-analysis include a shorter follow-up period (mean, 20.5 months) for subjects who underwent PAIR than for surgical control subjects (mean, 32 months), potentially providing insufficient time to detect all instances of disease recurrence in the former group. Furthermore, only 3 of the 21 PAIR studies had appropriate surgical control subjects. For our comparative analysis, we attempted to use relevant historical controls, choosing era-matched studies that would have used surgical techniques and advances available during the time period similar to that for patients undergoing PAIR. Although the type of surgery was usually stated in the surgical studies, outcomes were generally not given in relation to the operative type, thus making comparison of conservative versus radical procedure impossible.
In conclusion, compared with surgical intervention for cystic hepatic echinococcosis, PAIR plus albendazole or mebendazole is associated with greater clinical and parasitologic efficacy, less major and minor morbidity, lower rates of mortality and disease recurrence, and a shorter duration of hospitalization. As an initial treatment option or for patients whose illness fails to respond to drug therapy alone, PAIR is a safe and effective procedure of choice for patients with hepatic echinococcosis [4, 5] , and perhaps other anatomic sites of infection, such as lung, peritoneum, kidney, and other viscera [56] [57] [58] [59] . Surgery may be reserved for patients with hydatid cysts refractory to PAIR because of secondary bacterial infection or difficult-tomanage cyst-biliary communications [4, 5] .
